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Traumatic spinal cord injury: current concepts 
and treatment update
Traumatismo raquimedular: conceitos atuais e atualizações terapêuticas
Carolina Rouanet1, Danyelle Reges1, Eva Rocha1, Vivian Gagliardi1, Gisele Sampaio Silva1
Spinal cord injury (SCI) affects 1.3 million North Americans, 
with more than half occurring after trauma. In Brazil, few stud-
ies have evaluated the epidemiology of SCI with an estimated 
incidence of 16 to 26 per million per year. With the aging of 
the population, the incidence is expected to increase, mainly 
due to fall-related injuries. Direct lifetime costs can be as high 
as $1.1-$4.6 million per patient, and the consequences for the 
patients and their families can be devastating1,2.
Search strategy
A PubMed search for articles published up to September 
2016 was performed using the terms “Spinal Cord Injury” [Mesh] 
and (“traumatic” [Title/Abstract]), which returned 4,346 articles. 
Additionally, the reference lists of the most recent guidelines on 
the management of spinal cord injury were searched. Two review-
ers independently screened the article titles and abstracts. Articles 
with at least one abstract in English or Portuguese were searched.
Pathophysiology
The initial primary trauma causes mechanical injury to 
the spinal cord, a combination of compression, laceration, 
distraction or shearing. After the resulting damage to the 
microvasculature, progressive edema develops, ongoing isch-
emia worsens and a pro-apoptotic signaling is initiated. There 
is disruption of the blood-spinal cord barrier, influx of inflam-
matory cells, vasoactive peptides, and release of coagulation 
factors. These events promote thrombosis and spasm of the 
microvessels, leading to further hypoxia. An energetic crisis 
is installed, there is production of oxygen free radicals, and 
excitotoxicity and cytotoxic edema develop. With loss of the 
parenchymal volume, cystic cavities coalesce, generating a 
physical barrier to cell migration. Because of the distortion 
of the structural framework, regenerative attempts do not 
succeed. Proliferation of astrocytes and deposition of fibro-
blasts worsen the picture. The Rho-ROCK (rho-associated 
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ABSTRACT
Spinal cord injury (SCI) affects 1.3 million North Americans, with more than half occurring after trauma. In Brazil, few studies have evaluated 
the epidemiology of SCI with an estimated incidence of 16 to 26 per million per year. The final extent of the spinal cord damage results from 
primary and secondary mechanisms that start at the moment of the injury and go on for days, and even weeks, after the event. There is convincing 
evidence that hypotension contributes to secondary injury after acute SCI. Surgical decompression aims at relieving mechanical pressure on the 
microvascular circulation, therefore reducing hypoxia and ischemia. The role of methylprednisolone as a therapeutic option is still a matter of 
debate, however most guidelines do not recommend its regular use. Neuroprotective therapies aiming to reduce further injury have been studied 
and many others are underway. Neuroregenerative therapies are being extensively investigated, with cell based therapy being very promising.
Keywords: spinal cord injuries; spinal cord compression; neurosurgery; spinal cord regeneration; cell- and tissue-based therapy.
RESUMO
O traumatismo raquimedular (TRM) afeta 1.3 milhão de norte americanos, sendo mais da metade secundário a trauma.No Brasil, pouco estudos 
avaliaram sistematicamente a epidemiologia do TRM, mas estima-se uma incidência de 16 a 26 por milhão por ano. A extensão final do dano 
medular é resultante de mecanismos primários e secundários, que começam no momento do evento e prosseguem por dias e até semanas 
seguintes. Há fortes evidências de que a hipotensão contribua para danos secundários pós TRM. A cirurgia descompressiva visa a aliviar a 
compressão mecânica sobre a microcirculação, assim reduzindo isquemia e hipóxia. O papel da metilprednisolona no tratamento de pacientes 
com TRM é controverso, não sendo recomandada pela maior parte das diretrizes atuais. Terapias neuroprotetoras visando a reduzir injúria 
adicional foram e vêm sendo estudadas. Terapias neurorregenerativas estão sob investigação ampla, sendo a terapia celular uma forte promessa.
Palavras-chave: traumatismos da medula espinhal; compressão da medula espinal; neurocirurgia; regeneração da medula espinal; 
terapia baseada em transplante de células e tecidos.
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protein kinase) is activated and inhibits neurite outgrowth. 
Together, all those mechanisms contribute to the restriction 
of regeneration1,2. 
The final extent of spinal cord damage results from 
primary and secondary mechanisms that start at the 
moment of the injury and go on for days and even weeks. 
Neuroprotective agents attempt to avert specific second-
ary injuries and prevent neural damage, while neuroregen-
erative therapies act to promote axonal regrowth after the 
damage has occured1.
Neurological classification
After initial general stabilization, it is important to per-
form a thorough neurological examination. The American 
Spinal Injury Association (ASIA) standard for neurological 
and functional classification is the recommended preferred 
tool. It is important as a means of standardizing the initial 
and follow-up examinations, and also has a role in predicting 
the prognosis3.
The tool consists of two components, the sensitive and 
the motor. The sensitive component comprises the testing of 
a key point in each of the 28 dermatomes ( from C2 to S4-5) 
on the right and left sides. Light touch and pinprick sensation 
are also tested. Each modality is separately scored on a three-
point scale, ranging from 0 (absent) to 2 (normal or intact). 
The motor examination encompasses testing of key 
muscle functions corresponding to ten paired myotomes 
(C5-T1 and L2-S1). Voluntary external anal sphincter 
contraction should also be tested. The strength should be 
graded according to the Medical Research Council grading 
system, from 0 to 5. 
With that, the neurological level of injury is determined 
as the most caudal segment of the cord with intact sensation 
and antigravity muscle function strength (Figure 1). 
The ASIA Impairment Scale should be determined, as follows:
A = complete. No sensory or motor functions in sacral 
segments S4-S5.
B = sensory incomplete. Sensory but not motor function 
is preserved below the neurological level of injury including 
S4-S5 and no motor function is preserved more than three 
levels below the motor level on each side of the body.
C = motor complete. Motor function is preserved below 
the neurological level, and more than half the muscles 
below the neurological level of injury have a  muscle grade 
less than 3.
D = motor incomplete. Motor function is preserved below 
the neurological level, and at least half the muscles below the 
neurological level of injury have a muscle grade > 3.
E = Normal. Sensation and motor functions are normal in 
all segments tested4.
As previously mentioned, the ASIA Impairment Scale 
score has a prognostic value. Eighty-five percent of ASIA 
A patients will not regain function. Of the 15% who will 
improve, only 3% will have useful motor function. More 
than half (54%) ASIA B patients, and the vast majority (86%) 
of ASIA C-D patients will regain function5.
MOTOR
C5 - elbow flexors
C6 - wrist extensors
C7 - elbow extensors
C8 - finger flexors
T1 - finger abductors
Upper limb - maximum 50
L2 - hip flexors
L3 - knee extensors
L4 - ankle dorsiflexors
L5 - long toe extensors
S1 - ankle plantar flexors
Lower limb - maximum 50
SENSORY
Pin prick score - maximum 112
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Figure. American Spinal Injury Association (ASIA) Standard Neurological classification of spinal cord injury. Steps of required 
motor and sensory examinations.
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Imaging
According to the last SCI guideline, trauma patients who 
have complaints of neck pain, spinal tenderness, symptoms 
or signs of a neurological deficit related to the spine, and 
patients who cannot be clearly assessed (the ones who are 
unconscious, uncooperative, incoherent or intoxicated) need 
a radiographic study of the spinal cord3. 
The National Emergency X-Radiography Utilization Study 
(NEXUS) protocol was designed as an attempt to identify those 
at low risk for cervical fracture/subluxation/dislocation. It 
consists of five criteria: no posterior midline cervical tender-
ness, no intoxication, normal mental status, no other painful 
injuries and no neurological deficits. Patients meeting all of 
these criteria are at low risk of cervical injury and imaging of 
the neck or the spinal cord can be waived. The NEXUS proto-
col has a sensitivity of 99% and a negative predictive value of 
99.9% for cervical spinal cord injuries6.
Another protocol addressing the same issue is the 
Canadian C-Spine Rule, which consists of three questions: 
the presence of a high-risk factor that mandates radiography 
(age > 65 years, dangerous mechanism of trauma, or pares-
thesias in extremities), the presence of low risk factors allow-
ing safe assessment of the range of motion, and the ability to 
actively rotate the neck 45º to the left and right. The use of 
the Canadian C-Spine Rule protocol resulted in 100% sensi-
tivity for cervical spinal injury with a 42.5% specificity7.
The imaging modality of choice is computed tomography 
(CT). If it is not available, a three-view spine x-ray is recom-
mended (anteroposterior, odontoid and lateral views), being 
supplemented later by a CT scan3.
Magnetic resonance imaging should be obtained, when 
feasible, in the first 48 hours after the trauma. It can detect 
lesions in 6% of the cases in which the CT is normal, and is 
particularly useful for ligamentous lesions. It is also a valuable 
tool to classify severity and predict outcome based on the pres-
ence of hemorrhage, extent of edema, and severity of the initial 
compression. Intraspinal hemorrhages (> 1cm long) as well as 
longitudinal T2 signal changes > 3cm, are associated with poor 
prognosis. A normal initial magnetic resonance image is usu-
ally associated with complete recovery8. 
Airway management
Respiratory complications are the main cause of mor-
bidity and mortality in the acute phase of the SCI, with inci-
dence ranging from 36% to 83%. Reduced vital capacity, 
retention of secretions, and autonomic dysfunction all play 
a role. Up to two thirds of patients will have complications 
such as atelectasis, pneumonia, or respiratory failure that 
require mechanical ventilation9.
The injury level and the ASIA classification are the 
two most important predictors for the need of intubation. 
Virtually 100% of lesions above C5 require intubation (the 
phrenic nerve originates from C3-C5), which should be per-
formed electively rather than as an emergency. It is important 
to avoid hyperextension, rotation, and other movements of 
the neck during intubation. When possible, awake, fiberoptic 
intubation is preferred. In-line stabilization without traction 
is an alternative when a fiber optic laryngoscope or broncho-
scope is unavailable9.  
In selected patients with complete cervical lesions or in 
those with incomplete or lower lesions, conservative man-
agement might be an option. In such cases, lung function 
should be monitored closely with vital capacity, maximum 
inspiratory pressure and carbon dioxide partial pressure lev-
els. Those measures can predict the need for intubation9.
With regard to ventilator weaning, only 40% of patients 
with lesions above C4 are successfully extubated. Predictors 
of the need for tracheostomy are ASIA A lesions, extent of 
the lesion, smoking, and previous lung disease. Some studies 
advocate that early tracheostomy (within 10 days) in these 
patients leads to a shorter ICU stay and reduction in the 
length of time of mechanical ventilation10.
Cardiovascular management
Hypotension after SCI is frequent. It may be due to hypo-
volemia in a context of polytrauma, or due to the direct cer-
vical or thoracic spinal trauma itself, leading to neurogenic 
shock. Neurogenic shock results from the interruption of 
sympathetic tone due to disruption in supraspinal control, 
and an intact parasympathetic influence via the vagus nerve, 
leading to an imbalance in the autonomic control. There is, 
therefore, loss of peripheral vascular tone and bradycardia11. 
Although the deleterious consequences of hypotension in 
SCI have not been assessed in a controlled prospective way, 
there is convincing evidence that hypotension contributes to 
secondary injury after acute SCI, reducing spinal cord flow 
and perfusion. Based on this, the current recommendation is 
to strictly avoid hypotension, and maintain mean arterial pres-
sure (MAP) at 85-90mmHg for seven days after injury (level 
III evidence)3. In order to achieve that goal, the mainstay of 
treatment is intravenous fluid therapy (mainly with crystal-
loids) to maintain a euvolemic or slightly hypervolemic status, 
in association with vasopressors2. It is important to have inva-
sive blood pressure monitoring with an arterial line. 
The main predictors of poor cardiovascular function 
requiring resuscitation and support are high cervical and 
complete lesions12. Cardiovascular instability may be tran-
sient and episodic, but can also be recurrent in the first 
7–10 days after injury.
The best vasoactive amine is still a matter of debate. 
The last guideline does not address this controversy. A sys-
tematic review tried to answer several questions regarding 
the use of vasopressors in acute SCI. However, it was incon-
clusive in determining which vasopressor is better, what the 
optimal therapy duration is and what the MAP level is below 
which one should initiate vasopressor support13. 
The vasopressor selection may depend on the level of the 
SCI and on the patient’s hemodynamics. In cervical or high 
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thoracic lesions with both hypotension and bradycardia, 
a drug with chronotropic and inotropic effects as well as vaso-
constrictor properties might be required. Norepinephrine 
(or alternatively, dopamine) could be good options. For low 
thoracic lesions, where hypotension is usually the result of 
peripheral vasodilation, a pure vasopressor drug such as 
phenylephrine could be appropriate14. 
Recently, some studies have addressed the frequency of 
side effects and rates of complications related to the use of 
vasoactive drugs in this population. A high rate of cardiogenic 
complications was found, with up to 70% of patients experi-
encing at least one of the following: tachycardia, bradycardia, 
elevated troponin, new onset atrial fibrillation, atrial flutter, 
or eletrocardiogram ST changes consistent with ischemia. 
A higher rate of side effects with the use of dopamine com-
pared to norepinephrine and phenylephrine was described, 
especially in the population older than 55–60 years15,16,17.
Recently, Altaf and collaborators compared the effects 
of norepinephrine versus dopamine on MAP, the intrathe-
cal pressure (monitored with a lumbar intrathecal catheter) 
and spinal cord pressure perfusion (the difference between 
MAP and intrathecal pressure). The conclusion was that 
norepinephrine was able to maintain MAP with a lower 
intrathecal pressure and correspondingly higher spinal cord 
pressure perfusion18.
These findings have led to a non-inferiority trial design 
called the “Mean Arterial Blood Pressure Treatment for 
Acute Spinal Cord Injury”, comparing the avoidance of hypo-
tension (MAP ≥ 65mmHg) versus the induction of hyperten-
sion (MAP ≥ 85mmHg), which is currently recruiting patients 
and is expected to be completed in 201719.
Decompressive Surgery
Progressive edema and hemorrhage contribute to the 
ongoing mechanical pressure on the microvascular circula-
tion. Surgical decompression aims to relieve this pressure, 
thereby reducing secondary hypoxia and ischemia2.
Indications for surgery include significant cord compres-
sion with progressive neurological impairment and a fracture 
not amenable to, or not responding to, close reduction, such 
as unstable vertebral fractures.
The Surgical Timing in Acute Spinal Cord Injury Study 
was a prospective, observational study that compared 
patients who had undergone surgery before and after 24 
hours from injury. The first group was more than twice as 
likely to have a two grade ASIA Impairment Scale improve-
ment and a similar complication rate compared to the 
group with late surgery20.
Those findings were confirmed in a prospective Canadian 
cohort study even after adjusting for preoperative status and 
neurological level21.
With that, the concept of “time is spine” has emerged, and 
the ongoing recommendation is surgical decompression in 
the first 24 hours3.
The SCI-POEM is a European multicenter study that is 
currently recruiting patients with the aim to compare decom-
pression < 12hours versus > 12 hours until 14 days. The final 
report is planned to be published in the end of 201722.
Intravenous methylprednisolone
Methyprednisolone (MP) is a synthetic corticosteroid 
that upregulates anti-inflammatory factors and decreases 
oxidative stress, enhancing endogenous cell survival in ani-
mal models of SCI. It reduces edema, prevents intracellular 
potassium depletion and inhibits lipid peroxidation1.
Since the 1980s, clinical trials have been trying to demon-
strate its benefits in humans. The National Spinal Cord Injury 
Study I, published in 1984, examined 1000mg bolus MP fol-
lowed by the same dose daily for 10 days, compared to 100mg 
bolus and then daily. No difference in motor or sensitive neu-
rological recovery was observed between groups, and wound 
infections were more prevalent in the high-dose group23.  
The National Spinal Cord Injury Study II, published in 
1990, compared MP 30mg/kg intravenously followed by 
5.4 mg/kg/h over 23 hours to naloxone and placebo. At one 
year, there was no significant difference in neurological func-
tion among the groups. A subanalysis found that the sub-
set of patients who received the corticosteroid within eight 
hours had a modest improvement in motor recovery. Wound 
infections were more frequent among MP patients24.
The National Spinal Cord Injury Study III, published in 
1997, compared three treatment groups: MP for 48 hours, the 
same drug administered for 24 hours and tirilazad mesylate 
(a potent lipid peroxidation inhibitor). Patients were treated 
within eight hours of SCI. In a post hoc analysis, in patients 
treated between three to eight hours from trauma, the 
48-hour regimen was associated with a greater motor, but 
not functional, recovery. In addition, the group with the lon-
ger duration had more severe sepsis and pneumonia25. 
Recently, a meta-analysis and systematic review con-
cluded that evidence from multiple randomized controlled 
trials and also from observational studies do not support 
methylprednisolone use in acute SCI since it has no long-term 
benefits. Besides, it increases gastrointestinal hemorrhage 
and has a trend to increase overall adverse events26.
The last consensus does not recommend MP for treat-
ment of SCI3.
Neuroprotection
Neuroprotective agents aiming to reduce secondary insults 
are potential key therapies in SCI. Multiple approaches have 
been studied, and many others are currently under investigation.
Gangliosides are glycolipid molecules present in neuro-
nal membranes. Laboratory studies have shown that they 
can enhance axonal regeneration, besides having a variety of 
neuroprotective effects, such as prevention of apoptosis and 
anti-excitotoxic activity. GM-1 (Sygen) was suggested as a 
therapeutic option until the 2002 guideline (although without 
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demonstrated clinical benefit)27. However, a randomized 
controlled trial of the ganglioside compound reported no dif-
ference in neurological recovery after six months, therefore, 
it is no longer recommended3,28.
Naloxone, an opioid antagonist, was tested in the National 
Spinal Cord Injury Study II trial together with MP and pla-
cebo. The study was negative, with no differences in motor 
scores between groups24.
Nimodipine is an L-type calcium channel blocker thought 
to prevent calcium- dependent apoptotic enzymes and block 
presynaptic release of glutamate. In comparison with pla-
cebo, however, no difference in neurological status at one 
year was noted29.
Tirilazad mesylate, a drug that attenuates peroxidation of 
neuronal membranes, was analyzed together with MP in the 
National Spinal Cord Injury Study III trial, with no difference 
between groups. There are no placebo-controlled studies25.
In animal studies, hypothermia decreased basal meta-
bolic rate in the central nervous system, reduced inflamma-
tion, apoptosis, excitotoxicity, edema, gliosis, and increased 
angiogenesis. As well, traumatic SCI models showed 
improvement with the decreased temperature30. A small pilot 
study in humans with SCI exposed to hypothermia showed a 
trend towards neurological recovery (43% vs 21%) and no dif-
ference in complication rates31. Another study evaluated 35 
ASIA A patients who were treated with hypothermia (33ºC) 
for 48 hours, starting in the first six hours post-injury. Four 
patients converted to ASIA B in the first 24 hours. In the 
remaining patients, 35.5% showed an improvement of at 
least one grade on the ASIA scale at the latest follow-up32. 
These promising results led to a phase II/III trial named 
“The Acute Rapid Cooling Therapy for Injuries of the Spinal 
Cord”. This study (which is not yet recruiting) plans to evalu-
ate different durations of hypothermia, starting within six 
hours post-trauma.
Riluzole, a sodium-channel blocker, reduces second-
ary injury by blocking pathological activation of sodium 
channels and reducing the release of glutamate in preclini-
cal models of SCI. A phase I/II trial demonstrated a benefit 
in motor scores in patients treated with the drug33. A phase 
II/III trial, the Riluzole in Spinal Cord Injury Study, is ongo-
ing, to evaluate the aforementioned drug in cervical lesions. 
It will be completed in 201834.
Minocycline is an antibiotic with anti-inflammatory 
properties including inhibition of tumor necrosis factor 
alpha, interleukin 1 beta, cyclooxygenase-2 and nitric oxide 
synthase. In pre-clinical models, it decreased lesions sizes 
and neuron loss. In a phase II study, the ASIA motor score 
improved in patients treated with minocycline (p = 0.05)35. 
This led to a phase III trial, the Minocycline in Acute Spinal 
Cord Injury, which is currently recruiting patients until 201836. 
*Paralysis TMPtC: Neuroprotection: therapeutic hypothermia; 2014. Assessed August 2016.
Fibroblast growth factor has been shown to protect 
against excitotoxicity and to reduce free radical production 
in animal models of SCI. A fibroblast growth factor analogue 
called SUN 13837 was evaluated in a phase I/II trial com-
pleted in 2015, but results are still pending37.
Cytokine granulocyte colony stimulating factor is neuropro-
tective in SCI by promoting cell survival and inhibiting tumor 
necrosis factor alpha and interleukin 1 beta. There were two 
small, non-randomized studies that demonstrated improve-
ments in ASIA motor scores with the drug use38,39. 
Neuroregeneration
A wide number of strategies are being developed world-
wide to help recovery in SCI patients. There are numerous 
targets and therapeutic opportunities using endogenous and 
exogenous repair mechanisms. The aim is to surpass barriers 
to recovery such as the loss of structural framework, cystic 
cavitation, scarring and inhibitory molecular signaling2.
Cell-based therapies are promising modalities of regen-
eration. A wide number of cell types have been studied or are 
being evaluated in ongoing studies – embryonic stem cells, 
induced pluripotent stem cells, olfactory ensheathing cells, 
Schwann cells, mesenchymal cells, and activated autologous 
macrophages. In preclinical studies, cellular transplantation 
alone, or in combination with other therapies, was associ-
ated with neurological recovery, without any subtype show-
ing superiority over the other. Small human studies also dis-
closed some degree of improvement, with no major adverse 
events. However, it is important to notice that, independent 
of treatment, most patients will undergo some spontaneous 
recovery in the first six months after injury. Therefore, con-
founding factors cannot be excluded from these results1.
Embryonic and induced pluripotent stem cells are 
capable of remyelinate axons, modulate the inflammatory 
response, regenerate lost neural circuits and modify the 
microenvironment. Schwann cells are able to remyelinate 
central nervous system axons and, in animal models, have 
reduced cystic cavitation, enhanced tissue sparing and 
enhanced recovery. Olfactory ensheathing cells are phago-
cytes capable of clearing microbes and debris and also of 
secreting neurotropic factors. In animals, they enhanced 
axonal regeneration and remyelination and also improved 
outcomes. Mesenchymal cells can differentiate along their 
connective tissue lineages and modulate inflammatory 
response at systemic and local environment levels. They 
have been shown to decrease inflammatory cell infiltra-
tion, increase pro-survival trophic factor levels and pro-
mote tissue sparing1,2. 
It should be noted that cellular transplantation remains 
an investigational and experimental therapy, with no formal 
recommendations.  
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FINAL REMARKS
Spinal cord injury management has substantially changed 
over the last years. Key early interventions are increas-
ingly being recognized, as well as the need to better study 
these patients. Neuroprotective and neuroregenerative 
strategies are probably more effective when done together, 
and they are an extensive field of current and future 
research. The pending trial results can have a significant 
impact on the standard of care, given that even small 
motor or sensory improvements can have profound effects 
on patients’ lives. 
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